Get it on Google Play

FDA Approves Enhertu for HER2-Low Breast Cancer

August 5, 2022 11:51 AM EDT Send to a Friend
The U.S. Food and Drug Administration approved AstraZeneca (NYSE: AZN) and Daiichi Sankyo's Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login